Longevity Escape Velocity (LEV) is a technical term coined by the gerontologist Aubrey de Grey and now used more broadly: it names the threshold at which annual gains in healthy life expectancy exceed one year per calendar year. Below that line, each birthday still shortens the expected remainder of life. Above it, remaining lifespan grows faster than it is spent. LEV is not immortality; it is aging becoming a treatable condition rather than a fixed time budget.
The convergence behind the claim
Three distinct fields are converging on the aging phenotype: senolytics that clear damaged cells, partial cellular reprogramming (Yamanaka factors applied below the reprogramming threshold), and AI-driven target discovery that collapses drug-development timelines. None of the three is the full answer. Their convergence is what makes the LEV hypothesis a horizon to track rather than a curiosity.
Why it belongs in an abundance encyclopedia
Aging is the rate-limiting disease: cardiovascular disease, most cancers, neurodegeneration, and frailty share it as the underlying driver. Treating aging compresses morbidity and expands the productive window of a life, which is the health analog of Energy Abundance. Combined with Education Abundance, it makes serial careers and multi-decade learning projects the default rather than the exception.
Risks and open questions
Distributional capture is the obvious risk: a therapy that adds decades but costs millions per course reinforces existing inequality at a civilizational scale. The deeper open question is whether LEV arrives as a cluster of cheap, compounding interventions (more like statins) or as a high-priced platform (more like CAR-T). The answer will be partly scientific and partly a choice about Coordination Abundance and public-sector biotech funding.